1
AKTX
Akari Therapeutics develops antibody-drug conjugates (ADCs), which are biologics consisting of antibodies linked to payloads. The company's revenue model is based on the future sale of these biologic products, as well as licensing, milestones, and royalties from biopharmaceutical partners.
Akari Therapeutics
Biotechnology
1.23 Tn
8.77
+4.03%
-78.50%
—
—
—
2
LLY
Eli Lilly discovers, develops, manufactures, and markets branded prescription drugs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. Its revenue is primarily generated from the sale of branded pharmaceutical products like insulin analogs and GLP-1 receptor agonists.
Eli Lilly
Pharmaceuticals
1.11 Tn
1,178.70
+0.75%
+37.80%
39.38
13.93
1.08 Tn
3
JNJ
The company's Innovative Medicine segment generates significant revenue from branded prescription pharmaceuticals such as STELARA, TREMFYA, and XARELTO. These products are sold to retailers, wholesalers, and hospitals for the treatment of oncology, immunology, and cardiovascular diseases.
Johnson & Johnson
Pharmaceuticals
630.16 Bn
261.49
+1.95%
+36.85%
29.92
6.43
548.69 Bn
4
ABBV
AbbVie is a diversified pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as Vraylar, Ubrelvy, Qulipta, and Mavyret.
AbbVie
Pharmaceuticals
488.57 Bn
276.48
+1.49%
+19.85%
77.51
7.59
461.73 Bn
5
MRK
Merck's primary revenue driver is the sale of branded prescription pharmaceuticals and vaccines for human health, with 2025 pharmaceutical sales totaling $58,142 million. Key branded products cited include Keytruda, Gardasil, and Januvia.
Merck
Pharmaceuticals
359.15 Bn
145.57
+2.23%
+66.37%
113.32
5.40
313.58 Bn
6
NVS
Novartis is an innovative medicines company that researches, develops, manufactures, and markets branded prescription pharmaceuticals across therapeutic areas such as cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Its primary revenue is generated from the sale of these pharmaceutical products to wholesalers, health systems, and government agencies.
Novartis Ag
Pharmaceuticals
274.32 Bn
143.76
+0.45%
+9.69%
17.67
5.01
238.71 Bn
7
AZN
AstraZeneca is a global biopharmaceutical company that discovers, develops, and markets branded prescription medicines. Its revenue is primarily driven by the sale of branded pharmaceutical products such as Tagrisso, Farxiga, and Symbicort across various therapeutic areas.
Astrazeneca
Pharmaceuticals
246.73 Bn
159.18
+0.36%
-6.41%
23.62
4.27
220.50 Bn
8
AMGN
Amgen is explicitly described as a leading independent biotechnology company that researches, develops, and commercializes therapies derived from biological science. Its revenue is generated from the sale of therapeutic medicines such as Enbrel and Repatha, which are biologic products.
Amgen
Biotechnology
224.28 Bn
414.87
+1.82%
+40.43%
25.62
5.89
179.68 Bn
9
GILD
Gilead is a biopharmaceutical company that develops therapies derived from biological science, including monoclonal antibodies and CAR T cell therapies like Yescarta and Tecartus. Its revenue is driven by the sale of these biologic products and royalties from collaborations.
Gilead Sciences
Biotechnology
187.60 Bn
151.17
+2.77%
+29.49%
-58.00
6.16
161.71 Bn
10
NVO
Novo Nordisk discovers, develops, and markets branded prescription pharmaceuticals, specifically GLP-1 receptor agonists like Ozempic and Wegovy for obesity and diabetes. Its revenue is primarily generated from the sale of these branded pharmaceutical products.
Novo Nordisk A S
Pharmaceuticals
185.42 Bn
38.63
+1.26%
-34.17%
—
—
—
11
ABT
2nd
The Established Pharmaceutical Products segment markets branded generic pharmaceuticals and biosimilars, such as Creon and Synthroid, primarily in emerging markets.
Abbott Laboratories
Generic Drugs
172.35 Bn
99.60
+1.13%
-25.29%
31.95
3.70
143.43 Bn
12
PFE
Pfizer is a global biopharmaceutical company that discovers, develops, and markets a vast portfolio of branded prescription drugs and vaccines, including Eliquis, Prevnar, and Paxlovid. Its primary revenue is generated from the sale of these branded pharmaceutical products to hospitals, patients, and healthcare providers.
Pfizer
Pharmaceuticals
161.13 Bn
28.27
+1.58%
+12.00%
37.19
2.53
108.08 Bn
13
VRTX
Vertex is described as a global biotechnology company that develops therapies derived from biological science, including proteins and biologics. Its revenue is derived from the sale of biologic products, collaboration milestone payments, and royalties.
Vertex Pharmaceuticals
Biotechnology
129.23 Bn
510.08
+1.36%
+22.95%
29.38
10.27
101.23 Bn
14
BMY
Bristol Myers Squibb is a large pharmaceutical firm that discovers, develops, and markets a wide portfolio of branded prescription medicines such as Eliquis, Sprycel, and Abraxane. Its revenue is primarily generated from the sale of these innovative branded pharmaceuticals across multiple therapeutic areas.
Bristol Myers Squibb
Pharmaceuticals
120.74 Bn
59.11
-0.76%
+32.30%
13.00
2.45
72.02 Bn
15
GSK
GSK is a global biopharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded products such as Dovato, Cabenuva, and Nucala.
Gsk
Pharmaceuticals
100.33 Bn
46.50
-0.04%
+7.04%
31.78
4.62
81.91 Bn
16
MRNA
Moderna is a biotechnology company that researches and commercializes therapies derived from biological science, specifically messenger RNA (mRNA). Its revenue is generated from the sale of biologic products like Spikevax and mRESVIA, as well as collaboration and licensing revenue.
Moderna
Biotechnology
89.78 Bn
225.00
+14.21%
+717.29%
-28.42
40.29
69.13 Bn
17
REGN
Regeneron is a biotechnology company that develops and commercializes therapies derived from biological science, specifically using its VelociSuite and Trap technology to produce fully human antibodies and bispecific molecules. Its revenue is driven by the sale of biologic products such as EYLEA, Dupixent, and Libtayo, as well as collaboration and royalty payments.
Regeneron Pharmaceuticals
Biotechnology
76.74 Bn
746.54
+0.94%
+30.99%
17.73
4.94
42.95 Bn
18
COR
2nd
The company operates the MWI Animal Health business, which generates revenue through the distribution of animal health products and veterinary supplies to animal health providers.
Cencora
Animal Health
61.84 Bn
324.08
+0.87%
+3.17%
23.85
0.19
50.93 Bn
19
ARGX
Argenx is a biopharmaceutical company that develops and commercializes antibody-based therapeutics, such as VYVGART, which is an FcRn inhibitor. Its revenue is derived from the sale of these biologic products and from milestone payments and royalties from collaborations with partners like Zai Lab and AbbVie.
Argenx Se
Biotechnology
51.06 Bn
825.03
+0.78%
+2.50%
29.48
9.77
-1.84 Tn
20
SNY
Sanofi is a global pharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded medicines such as Dupixent for immunology and Sarclisa for oncology.
Sanofi
Pharmaceuticals
48.86 Bn
40.07
-0.40%
-17.92%
10.49
0.91
15.64 Bn
21
TEVA
Teva is described as a biopharmaceutical company with a strong generics business, ranking among the top three global suppliers of generic prescription drugs. Its revenue is primarily driven by a broad generic portfolio including oral solids, injectables, and inhalants marketed to wholesalers and pharmacies.
Teva Pharmaceutical Industries
Generic Drugs
47.86 Bn
41.07
+4.69%
+104.94%
67.77
2.76
34.71 Bn
22
IDXX
The company's primary business is focused on the animal health market, providing diagnostic products and services for companion animals, livestock, poultry, and dairy. Key products include the IDEXX VetLab suite, Catalyst One Chemistry analyzer, and tests for Bovine Viral Diarrhea Virus.
Idexx Laboratories
Animal Health
40.86 Bn
518.00
+0.95%
-17.61%
35.89
8.97
40.07 Bn
23
RVMD
Revolution Medicines is a clinical-stage company developing small-molecule RAS(ON) inhibitors for cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. Its core business is the discovery and development of branded prescription pharmaceuticals based on its proprietary tri complex technology platform.
Revolution Medicines
Pharmaceuticals
40.65 Bn
189.76
+0.87%
+298.49%
-22.63
—
40.65 Bn
24
ONC
BeOne Medicines discovers, develops, and markets branded prescription drugs for oncology, specifically hematology and solid tumors. Its primary revenue is derived from the sales of branded medicines such as BRUKINSA and TEVIMBRA.
BeOne Medicines
Pharmaceuticals
40.06 Bn
354.47
+1.24%
+5.56%
60.32
6.54
21.59 Bn
25
BIIB
Biogen is a biopharmaceutical company that researches and commercializes therapies derived from biological science, such as monoclonal antibodies and recombinant proteins. Its revenue is driven by biologic products like SPINRAZA for spinal muscular atrophy and LEQEMBI for Alzheimer's disease.
Biogen
Biotechnology
33.35 Bn
225.71
+3.33%
+50.87%
39.94
3.33
20.01 Bn